Drug Discovery

A new compound developed at Vanderbilt treats multiple symptoms of schizophrenia in an animal model, without causing sedation. Read More

Vanderbilt University Medical Center and Ono Pharmaceutical Group, an international company based in Japan, have signed a drug discovery agreement. Read More

Structural and molecular details of an anti-fungal target's interaction with inhibitors suggest ways to design better treatments for fungal infections. Read More

La Jolla Pharmaceutical Co. and Vanderbilt University have signed a research and license agreement covering Vanderbilt’s research program and intellectual property rights related to compounds that block bone morphogenetic protein (BMP) type-I receptors. The compounds have therapeutic potential in a broad range of diseases, including rare genetic disorders. Read More

Vanderbilt investigators have developed a new algorithm to understand the networks of signaling molecules that control drug action. Read More

Inhibitors of the enzyme phospholipase D1 suppress the replication of HIV-1, Vanderbilt investigators have discovered. Read More

Vanderbilt University is partnering with the William K. Warren Foundation of Tulsa, Oklahoma, on research aimed at improving the treatment of schizophrenia and other forms of serious mental illness. Read More

New findings underscore the attractiveness of the HIV capsid – the structure that encloses the viral genome – as a therapeutic target. Read More

A family of single-celled organisms that thrive in environments too extreme for most other species to survive may be an untapped source of new antibacterial drugs. Read More

A receptor in the brain that regulates appetite and body weight has now been found in L cells, key regulatory cells in the gut, providing the pharmaceutical industry with a novel drug target for both obesity and diabetes, a Vanderbilt University-led research team reported this week. Read More

A Vanderbilt lung cancer patient’s exceptional response to different types of therapies spurred research that suggests lung cancer patients with specific gene alterations may benefit from combination therapy that targets two different cancer pathways. Read More

Compounds developed at Vanderbilt University may offer a new way to block influenza infection. Read More

Inhibition of BMP growth factor signaling reduces breast tumor burden and metastasis. Read More

A new compound that activates potassium channels could be used to treat disorders of glucose homeostasis. Read More

A compound identified at Vanderbilt has therapeutic potential in protecting the kidney filter barrier. Read More

Vanderbilt investigators used an in vivo screen in zebrafish to identify a potential new anti-cancer drug. Read More

Top chemists from around the country will be on hand March 12 to celebrate the 10th anniversary of the Vanderbilt Institute of Chemical Biology (VICB), a brave experiment that helped jumpstart the University’s robust drug discovery initiative. Read More

A careful look at how the body’s natural defenses disarm virulent strains of influenza hints at the possibility of a way to fight the flu. Read More

If you drop by the American Museum of Natural History the next time you visit New York, there is a good chance that you will see an exhibit highlighting Vanderbilt chemist Brian Bachmann’s "caving for drugs" research. Read More

When discovering drugs for brain disorders, it’s important to test the candidates in multiple ways to avoid advancing those with restricted physiological effects. Read More